Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nuance Pharma
Bavarian Nordic is planning regulatory submissions on both sides of the Atlantic next year for its vaccine against chikungunya virus, CHIKV VLP, after it demonstrated protection from the mosquito-borne disease in a second Phase III study.
The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.
GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.